Suneva Medical, Inc., a privately-held aesthetics company, announced today that the U.S. Food and Drug Administration (FDA) has approved the dermal filler, Bellafill, for the treatment of acne scars. Bellafill represents a significant clinical advancement as the only filler on the market approved for this disfiguring skin condition. Acne is the most common skin disorder in the U.S., affecting 40-50 million people and up to 95% of people with acne may go on to suffer from scarring. Bellafill was studied extensively prior to its FDA approval and proven to be safe and effective for the correction of moderate to severe, atrophic, distensible facial acne scars on the cheek in patients over the age of 21 years.

"These types of acne scars affect millions of people and can have a profoundly negative impact on their self-esteem and self-confidence," said Nicholas L. Teti, Jr., Chairman and Chief Executive Officer at Suneva Medical. "The results of this rigorous clinical study prove that Bellafill® reduces the appearance of acne scars—providing a solution to this widespread skin condition that previously had limited treatment choices. Bellafill can have a transformational effect on a patient's appearance and in turn, we hope an improvement in quality of life."

For more details, go to: http://www.sunevamedical.com/bellafill-receives-fda-approval-for-treatment-of-acne-scars